UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 831

Sortiert nach

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary

Gastroenterology (New York, N.Y. 1943), 2020-07, Vol.159 (1), p.350-357

2020

Volltextzugriff (PDF)

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data

Journal of Crohn's and colitis, 2020-02, Vol.14 (2), p.192-204

2020

Volltextzugriff (PDF)

Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience

Inflammatory bowel diseases, 2018-02, Vol.24 (3), p.490-501

2018

Volltextzugriff (PDF)

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry

The American journal of gastroenterology, 2014-02, Vol.109 (2), p.212-223

2014

Volltextzugriff (PDF)

Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease

PloS one, 2017-08, Vol.12 (8), p.e0182900-e0182900

2017

Volltextzugriff (PDF)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

BMC gastroenterology, 2022-12, Vol.22 (1), p.501-501, Article 501

2022

Volltextzugriff (PDF)

Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis

Digestive diseases (Basel), 2022, Vol.40 (5), p.553-564

2022

Volltextzugriff (PDF)

Targeted mutational analysis of inflammatory bowel disease–associated colorectal cancers

Human pathology, 2019-07, Vol.89, p.44-50

2019

Volltextzugriff (PDF)

Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch–Anal Anastomosis in Pediatric Ulcerative Colitis

Inflammatory bowel diseases, 2022-09, Vol.28 (9), p.1386-1394

2022

Volltextzugriff (PDF)

P026 Assessment of Contributing Factors for Fistula Development in Patients with Inflammatory Bowel Disease Treated by Proctocolectomy with Ileal Pouch-Anal Anastomosis

The American journal of gastroenterology, 2020-12, Vol.115 (Suppl 1), p.S7-S7

2020

Volltextzugriff (PDF)

Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?

Gastrointestinal endoscopy, 2007-06, Vol.65 (7), p.998-1004

2007

Volltextzugriff (PDF)

The pharmacoeconomics of biologic therapy for IBD

Nature reviews. Gastroenterology & hepatology, 2010-02, Vol.7 (2), p.103

Cohen, Russell D

2010

Volltextzugriff (PDF)

Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

Journal for immunotherapy of cancer, 2019-01, Vol.7 (1), p.1-1, Article 1

2019

Volltextzugriff (PDF)

Inflammatory Bowel Disease: Diagnosis and Therapeutics

Third edition., 2017

Volltextzugriff (PDF)

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2021-03, Vol.160 (4), p.1131-1139

2021

Volltextzugriff (PDF)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis

Intestinal research, 2022, 20(2), , pp.240-250

2022

Volltextzugriff (PDF)

Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease

Intestinal research, 2022, 20(3), , pp.303-312

2022

Volltextzugriff (PDF)

Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis

Digestive diseases and sciences, 2022-11, Vol.67 (11), p.5010-5013

2022

Volltextzugriff (PDF)

Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis

Therapeutic advances in gastroenterology, 2023-01, Vol.16, p.17562848231184985-17562848231184985

2023

Volltextzugriff (PDF)

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis

BMC gastroenterology, 2012-09, Vol.12 (1), p.132-132, Article 132

2012

Volltextzugriff (PDF)

Digging into the Histology

The New England journal of medicine, 2023-10, Vol.389 (14), p.1321-1326

2023

Volltextzugriff (PDF)

Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines

Clinical gastroenterology and hepatology, 2018-01, Vol.16 (1), p.99-105

2018

Volltextzugriff (PDF)

Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center

Clinical gastroenterology and hepatology, 2024-06, Vol.22 (6), p.1336-1338.e2

2024

Volltextzugriff (PDF)

Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease

Inflammatory bowel diseases, 2023-10, Vol.29 (10), p.1658-1661

2023

Volltextzugriff (PDF)

Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center

Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2407-2409.e2

2023

Volltextzugriff (PDF)

1 – 25 von 831

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(699)
Mit Volltextzugriff
(707)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data

Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry

Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis

Targeted mutational analysis of inflammatory bowel disease–associated colorectal cancers

Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch–Anal Anastomosis in Pediatric Ulcerative Colitis

P026 Assessment of Contributing Factors for Fistula Development in Patients with Inflammatory Bowel Disease Treated by Proctocolectomy with Ileal Pouch-Anal Anastomosis

Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?

The pharmacoeconomics of biologic therapy for IBD

Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

Inflammatory Bowel Disease: Diagnosis and Therapeutics

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis

Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease

Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis

Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis

Digging into the Histology

Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines

Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center

Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease

Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center

Suchergebnisse filtern